Saluda Medical was founded in 2013 for the purpose of transforming patients’ lives with disruptive neuromodulation solutions. Built on more than 10 years of advanced research development and clinical experience, Saluda is the first to directly measure the spinal cord’s physiologic response to stimulation using Evoked Compound Action Potentials (ECAPs) to pioneer smart neuromodulation therapy.
Our first product, the Evoke® System, is the only ECAP-controlled closed-loop spinal cord stimulation (SCS) system and is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain.
The Evoke System instantaneously reads, records, and responds to the nerves’ response to stimulation to provide continually optimized therapy and is proven to be superior to open-loop SCS for the treatment of overall trunk and/or limb pain. 12-month results from the EVOKE Study, the first double-blind randomized controlled trial (RCT) used in support of Premarket Approval (PMA) in spinal cord stimulation history, were published in The Lancet Neurology and 24-month results have since been published JAMA Neurology. Both studies are poised to set new clinical standards for long-term pain relief and improvements in physical and emotional functioning, sleep quality and health-related quality of life.
Visit our careers site at: https://www.saludamedical.com/careers/. Submit your application with your CV/resume and a cover letter (optional).
Recruitment process: